Purple Biotech Ltd. — Proxy Solicitation & Information Statement 2016

May 24, 2016

Proxy Statement – Part Two

Company name: Kitov Pharmaceuticals Holdings Limited, public company no. 520031238

Company address (for submission and delivery of proxy statements): One Azrieli Center, Round Tower, 23rd Floor, Tel Aviv, Israel

Meeting date: Monday, June 27, 2016 at: 4:30 p.m. (Israel Time).

Date of adjourned meeting: Monday, July4, 2016 at: 4:30 p.m. (Israel Time).

Meeting type: Special General Meeting (the "Meeting").

Record Date: Close of business in New York on Wednesday, May 25, 2016.

Shareholder Details

Shareholder Name: ___________________

ID no.: ______________________

For shareholders who are not in possession of an Israeli ID card:

Passport no.: ______________________

Country of Issue: ______________________

Valid Until: _______________________

For shareholders that are corporations:

Corporation no. : _____________________

Country of Incorporation: ___________________

Is the Shareholder any of the following¹ :

A "Principal Shareholder"2 :	Yes / No
A "Senior Officer of the Company"3 :	Yes / No
An "Institutional Investor"4 :	Yes / No

3 As defined in Section 37(d) of the Securities Law ¹ Please circle the relevant possibility in each of the sections.

² As defined in Section 1 of the Securities Law, 5728-1968 (hereinafter: the "Securities Law")

⁴ As defined in Regulation 1 of the Supervision of Financial Services Regulations (Provident Funds)(Participation of a Management Company

at a General Meeting), 5769-2009 as well as a Manager of Mutual Funds as per the meaning in the Mutual Funds Law, 5754-1999

Manner of Voting:

Matter	Manner of voting			Do you have a Personal Interest in the Matter of
			the Proposal?
	For	Against	Abstain	Yes	No
Proposal 1 To approve the Kitov Pharmaceuticals Holdings Ltd. 2016 Equity-Based Incentive Plan to qualify for incentive stock options for US tax purposes.
Proposal 2 To approve an amendment to the terms of office and compensation of Mr. Isaac Israel, a member of the Board of Directors and Chief Executive Officer of the Company, including the grant of equity based incentive compensation.
Proposal 3 To approve the grant of equity-based incentive compensation to Mr. Simcha Rock, a member of the Board of Directors and Chief Financial Officer of the Company.
Proposal 4 To approve an amendment to the terms of office and compensation of Dr. John Paul Waymack, the Chairman of the Board of Directors and Chief Medical Officer of the Company, including the grant of equity based incentive compensation.

Mark X or V clearly in the appropriate column, in accordance with your voting decision.

Details:

Following are details in connection with my status as an interested party, as defined in section 1 of the Companies Law, for the purpose of the proposed engagement:

For shareholders holding shares through a stock exchange member (in accordance with Section 177(1) of the Companies Law, 5799 - 1999), this Voting Slip is only valid when accompanied by an certification of ownership. For shareholders registered in the Company's shareholder registry – this Voting Slip will only be valid when accompanied by a photocopy of an ID / passport / certificate of incorporation.